Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis

被引：0
|
作者：
Mehling, Matthias [1 ,2 ]
Lindberg, Raija L. [1 ,2 ]
Kuhle, Jens [1 ,2 ]
Vedrine, Corinne [3 ]
Kappos, Ludwig [1 ,2 ]
Brinkmann, Volker [3 ]
机构：
[1] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland
[3] Novartis Inst Biomed Res, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS | 2008年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S234 / S234
页数：1
相关论文
共 50 条
  • [21] High Bioavailability and Long Half-Life of Oral Fingolimod (FTY720), an Investigational Treatment for Multiple Sclerosis
    Slade, Alan
    Schmouder, Robert
    Kovarik, John
    Gschwind, Hans-Peter
    David, Olivier
    NEUROLOGY, 2009, 72 (11) : A358 - A359
  • [22] Th17 mediated recurrence of virus-induced immunopathology following discontinued FTY720 treatment
    Sehrawat, Sharvan
    Reddy, Pradeep
    Suryawanshi, Amol
    Khatri, Madhu
    Rouse, Barry
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [23] IL-17-producing cells in oral mucosal on patients with oral lichen plans
    Santos, Antonio Manuel Sequeira
    Didona, Dario
    Cunha, Tomas
    Mughal, Mudassar
    Berg, Barbara
    Schinner, Jona
    Worzfeld, Thomas
    Hertl, Michael
    Mayer, Johannes
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 88 - 88
  • [24] Lack of Interaction between Fingolimod (FTY720) and Oral Contraceptives, and Pregnancy Experience in the Clinical Program of Fingolimod in Multiple Sclerosis
    Collins, William
    Francis, Gordon
    Koren, Gideon
    Karlsson, Goeril
    Heining, Peter
    David, Olivier
    Zhang, Xioli
    Schmouder, Robert
    Jetty, Balaji
    Cohen, Jeffrey
    Kappos, Ludwig
    NEUROLOGY, 2011, 76 (09) : A609 - A609
  • [25] FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis
    Luessi, Felix
    Kraus, Stefan
    Trinschek, Bettina
    Lerch, Steffen
    Ploen, Robert
    Paterka, Magdalena
    Roberg, Torsten
    Poisa-Beiro, Laura
    Klotz, Luisa
    Wiendl, Heinz
    Bopp, Tobias
    Jonuleit, Helmut
    Jolivel, Valerie
    Zipp, Frauke
    Witsch, Esther
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (14) : 1811 - 1822
  • [26] Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
    Comi, G.
    O'Connor, P.
    Montalban, X.
    Antel, J.
    Radue, E-W
    Karlsson, G.
    Pohlmann, H.
    Aradhye, S.
    Kappos, L.
    MULTIPLE SCLEROSIS, 2010, 16 (02): : 197 - 207
  • [27] Comparison of Peripheral Blood Th17 Cells and Associated Cytokines in Fingolimod-Receiving and Untreated Multiple Sclerosis Patients
    Eken, Ahmet
    Yetkin, Mehmet Fatih
    Okus, Fatma Zehra
    Erdem, Serife
    Cakir, Mustafa
    Haliloglu, Yesim
    Azizoglu, Zehra Busra
    Donmez Altuntas, Hamiyet
    Mirza, Meral
    Canatan, Halit
    TURKISH JOURNAL OF IMMUNOLOGY, 2019, 7 (02): : 69 - 75
  • [28] Characterizing IL-17-producing CD8+T cells in multiple sclerosis
    Willing, Anne
    Steinbach, Karin
    Ufer, Friederike
    Friese, Manuel A.
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 167 - 167
  • [29] Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment
    Buehler, Ulrike
    Fleischer, Vinzenz
    Luessi, Felix
    Rezk, Ayman
    Belikan, Patrick
    Graetz, Christiane
    Gollan, Rene
    Wolf, Christina
    Lutz, Jens
    Bar-Or, Amit
    Siffrin, Volker
    Zipp, Frauke
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (04) : 567 - 576
  • [30] Oral fingolimod (FTY720) in multiple sclerosis Two-year results of a phase II extension study
    O'Connor, P.
    Comi, G.
    Montalban, X.
    Antel, J.
    Radue, E. W.
    de Vera, A.
    Pohlmann, H.
    Kappos, L.
    NEUROLOGY, 2009, 72 (01) : 73 - 79
12345